Investment Rating - The investment rating for the company is "Buy" [23][30]. Core Insights - The company has shown significant growth in its software sales, achieving revenue of 683 million RMB, a year-on-year increase of 20.18%, driven by the maturity of products like Hi-HIS and an optimized customer structure [2]. - The company secured 29 software orders exceeding 10 million RMB in the smart hospital and public health sectors, totaling nearly 500 million RMB [2]. - The sales of the company's smart medical insurance systems increased by 204.58%, with the contract number for the DRG/DIP product line growing by 217.39% and the collection amount increasing by 463.43% [2]. - The company is expected to achieve revenues of 2.023 billion RMB, 2.555 billion RMB, and 3.241 billion RMB for the years 2024, 2025, and 2026, respectively, with growth rates of 25.20%, 26.31%, and 26.82% [23][26]. Summary by Sections Performance Review - In 2023, the company reported total revenue of 1.616 billion RMB, a 5.81% increase year-on-year, and a net profit attributable to shareholders of 37 million RMB, a decrease of 13.93% [22]. Business Analysis - The company has successfully launched the CTasy 1.0 electronic medical record product in collaboration with Philips, which is expected to become a new growth engine [23]. - The partnership with Philips extends beyond software sales to include medical device sales and agency services [23]. Profit Forecast - The forecast for net profit attributable to shareholders is 311 million RMB, 417 million RMB, and 515 million RMB for 2024, 2025, and 2026, respectively, with substantial growth rates of 746.42%, 34.35%, and 23.35% [23][26].

Health Solutions and Services - The company has established a comprehensive smart health solution to support regional health information service systems, focusing on achieving full population coverage and integrated health information services[1]. - The company has been awarded a 10-year franchise by the health bureau of a city in Guangdong province to operate a health service platform, integrating various health services and promoting the city's health industry development[5]. - The company is participating in health city construction in a city in Zhejiang province, aiming to enhance medical service efficiency and promote equal access to healthcare services[5]. - The company has implemented a new service model that integrates medical and elderly care services, enhancing community support for the elderly[5]. - The company has developed a community health service information system in a provincial capital city, standardizing electronic health records for residents[3]. - The company has upgraded the information technology of a nursing home in Suzhou, integrating internet and IoT services to improve management and care quality[3]. - The "Health Wenzhou" platform achieved over 1 million user connections and covered 310 medical institutions, while "Health Zhongshan" registered 3.14 million users[44]. Technology and Innovation - The company has formed a strategic partnership with Zhejiang University to advance AI technology in clinical medicine and public health[11]. - The company has launched the CareSync electronic medical record product in collaboration with Philips, designed to meet the needs of various healthcare service providers[14]. - The company has achieved a four-level or above rating for interconnectivity with 39 clients, facilitating data sharing among healthcare institutions[13]. - The company has completed multiple projects aimed at enhancing emergency medical processes and integrating AI technologies into healthcare services, achieving all technical indicators[33]. - The company’s smart medical assistant has been successfully implemented in the Zhejiang University Medical College Affiliated Obstetrics and Gynecology Hospital[19]. - The company is actively participating in industry forums and standard-setting for medical IoT, reinforcing its position as a leading enterprise in the sector[16]. - The company is focusing on the integration of AI into healthcare, developing a unified platform that aggregates various AI applications to provide customized solutions for clients[114]. - The company is developing a smart medical imaging big data analysis platform to improve diagnostic accuracy and reduce costs for patients[74]. Financial Performance and Investments - As of the end of the reporting period, the new smart medical insurance business has covered 13 provinces and 11 cities, with sales increasing by 204.58% year-on-year in 2023; the DRG/DIP product line saw contract numbers rise by 217.39% and collection amounts by 463.43%[17]. - Research and development investment reached ¥339,476,026.88 in 2023, accounting for 21.01% of total revenue, an increase from 20.83% in 2022[34]. - The company reported a revenue growth of 15% year-over-year for the fiscal year 2023, reaching a total of 1.2 billion RMB[200]. - The company has a remaining balance of ¥24.52 million in raised funds as of December 31, 2023, which will be transferred to the company's basic settlement account for working capital[75]. - The total investment amount for the reporting period was ¥386,482,666.01, a decrease of 29.14% compared to ¥545,387,398.25 in the same period last year[85]. - The company reported a significant increase in trading financial assets, with a fair value change of ¥42,378.08 and a purchase amount of ¥117,100,000.00 during the reporting period[65]. - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[161]. Market Strategy and Growth - The company is expanding its innovative business segments and exploring sustainable development in its operations[14]. - The company is actively responding to new economic and industrial conditions by promoting new product development and technological innovation while expanding its market reach and national sales network[177]. - The company aims to strengthen its market position and enhance its core competitiveness by broadening its product line and health service ecosystem to improve profitability[178]. - The company is focusing on expanding its market presence and adjusting product development strategies based on user demand and market competition, while maintaining robust financial controls[154]. - The company is exploring potential acquisitions to enhance its service offerings, with a budget of 200 million RMB allocated for this purpose[200]. - Market expansion plans include entering three new provinces in China, targeting a 10% market share in these regions by 2025[200]. Challenges and Risks - In 2023, the company faced increased personnel costs and implementation expenses due to rapid order growth, leading to a decline in profit performance[40]. - The company acknowledges the uncertainty in its operations due to potential changes in national policy and macroeconomic conditions that could affect the healthcare information technology sector[195]. - The company faces risks related to market competition and potential resource shortages that could impact its market expansion plans[169]. - The company is actively managing risks related to external acquisitions and the potential impairment of goodwill due to changes in the macroeconomic environment[159]. - The company is implementing measures to balance project implementation and improve cash collection processes to mitigate seasonal operational risks[157]. Research and Development - The number of R&D personnel constitutes 35.54% of the workforce, reflecting a slight decrease from 36.20%[30]. - The company aims to enhance its R&D efforts by collaborating with renowned universities and research institutions to develop new products, addressing the risks associated with technology and product development[152]. - The company plans to enhance its R&D investment and closely monitor industry trends and innovations to maintain its core competitive advantages in user numbers and technology[172]. - The company is committed to enhancing its talent management strategies to retain high-level technical and managerial talent, ensuring stability and productivity within its core team[128]. Future Outlook - The company has provided a revenue guidance of 1.5 billion RMB for the next fiscal year, representing a projected growth of 25%[200]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2024[200]. - The company anticipates a gradual recovery in the healthcare informationization industry despite facing challenges in 2023[40]. - The company aims to transition from an IT information product service company to a technology cloud ecosystem enterprise, following the "Health China 2030" plan and the "HDAI" strategy for integrated medical and health intelligent product development[110].

证券代码：300451 证券简称：创业慧康 公告编号：2024-018 创业慧康科技股份有限公司 第八届监事会第四次会议决议公告 本公司及监事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届监事 会第四次会议的通知于 2024 年 4 月 2 日以邮件、传真等方式向各位监事发出， 并于 2024 年 4 月 12 日在公司二楼会议室以现场会议的方式召开。会议应到监事 3 名，实到监事 3 名。会议的召开及表决符合《中华人民共和国公司法》《创业 慧康科技股份有限公司章程》等有关规定。 经表决，形成如下决议： 一、审议通过了《关于<2023 年度监事会工作报告>的议案》 本议案尚需提交 2023 年年度股东大会审议。 二、审议通过了《关于<2023 年年度报告及摘要>的议案》 经审核，监事会认为：董事会编制和审核公司 2023 年年度报告的程序符合 法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司 2023 年度经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日刊登在中 ...

经核查独立董事蔡家楣先生、刘海宁先生、谭青女士和凌云先生的任职经历 以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况。因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立 性的相关要求。 创业慧康科技股份有限公司 董事会 2024 年 4 月 12 日 创业慧康科技股份有限公司 董事会关于独立董事独立性自查情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等要求，创业慧康科技股份有限公司（以下简称"公司"）董事会，就 公司在任独立董事蔡家楣先生、刘海宁先生、谭青女士和凌云先生的独立性情况 进行评估并出具如下专项意见： ...

2023 年度董事会工作报告 2023 年度，创业慧康科技股份有限公司（以下简称"创业慧康"或"公司"） 董事会严格按照《公司法》《证券法》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等法律法规以及《公司章程》《董事会议 事规则》等规章制度的规定，切实履行公司及股东赋予董事会的各项职责，认真 贯彻执行股东大会通过的各项决议，勤勉尽责地开展各项工作，推动公司治理水 平的提高和公司各项业务发展，积极有效地发挥了董事会的作用。现将董事会 2023 年主要工作情况报告如下： 创业慧康科技股份有限公司 | 序号 | 会议届次 | 召开日期 | 会议审议议案 | | --- | --- | --- | --- | | | | | 《关于<2022 年度总经理工作报告>的议 | | | | | 案》 | | | | | 《关于<2022 年度董事会工作报告>的议 | | | | | 案》 | | | | | 《关于<2022 年年度报告及摘要>的议案》 | | | | | 《关于<2022 年度财务决算报告>的议案》 | | | | | 《关于 2022 年年度利润分配预案的议案》 | | ...

关于创业慧康科技股份有限公司2023年度募集资金 存放与使用情况的专项核查报告 中信证券股份有限公司 截至 2023 年 12 月 31 日，募集资金余额为 24.52 万元（均系募集资金专户 产生的利息收入及结构性存款收益扣除银行手续费等的净额）。 中信证券股份有限公司（以下简称"中信证券"）作为创业慧康科技股份有 限公司（以下简称"创业慧康"、"公司"）向特定对象发行股票的保荐机构，根 据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》等有关规定，就公司 2023 年度向特定对象发 行股票募集资金的存放与使用情况进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准创业慧康科技股份有限公司非公 开发行股票的批复》（证监许可〔2020〕1094 号），公司由主承销商中信证券股 份有限公司采用非公开发行方式，向特定对象发行人民币普通股（A 股）股票 7,980.6759 万股，发行价为每股人民币 16 ...

创业慧康科技股份有限公司 2023 年度监事会工作报告 2023 年，监事会严格按照《公司法》《证券法》《公司章程》《监事会议 事规则》和有关法律、法规的要求，从切实维护公司利益和广大股东权益出发， 认真履行了监督职责。报告期内召开的监事会详细信息如下： 一、监事会工作情况 2023 年度公司监事会共召开会议 9 次。监事会的召开、决议内容的签署以 及监事权利的行使符合《公司法》《公司章程》和《监事会议事规则》的相关规 定，具体情况如下： | 序号 | 届次 | | 召开日期 | | | | 会议审议议案 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 《关于<2022 年度监事会工作报 | | | | | | | | | 告>的议案》 | | | | | | | | | 《关于<2022 年年度报告及摘要> | | | | | | | | | 的议案》 | | | | | | | | | 《关于<2022 年度财务决算报告> | | | | | | | | | 的议案》 | | | | | | | | | 《关于 202 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-006 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届董事 会第五次会议的通知于 2024 年 4 月 2 日以邮件、电话等方式向各位董事发出， 并于 2024 年 4 月 12 日在公司二楼会议室以现场会议的方式召开。会议应到董事 11 名，实到董事 11 名，公司部分监事、高级管理人员列席了会议。会议的召开 及表决符合《中华人民共和国公司法》《创业慧康科技股份有限公司章程》等有 关规定。 此次会议由董事长张吕峥先生主持，参会董事认真审议后，依照有关规定通 过以下几项决议： 一、审议通过了《关于<2023 年度总经理工作报告>的议案》 表决结果：此项议案以 11 票赞同，0 票反对，0 票弃权，议案获得通过。 二、审议通过了《关于<2023 年度董事会工作报告>的议案》 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的《2023 年度董事会工作报告》及独立董事《2023 年 度述职报告》。 表决结果：此项议案以 11 票赞同，0 票反对，0 票弃权，议案获得通过。 本议案尚需 ...

创业慧康科技股份有限公司 独立董事专门会议工作制度 二〇二四年四月 独立董事专门会议工作制度 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、深圳证 券交易所（以下简称"深交所"）业务规则和《公司章程》的规定，认真履行职 责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益， 保护中小股东合法权益。 第四条 独立董事专门会议根据工作需要，采取不定期方式召开。召开独立 董事专门会议，应在会议召开前三天以专人送达、电子邮件或其他方式通知全体 独立董事。经全体独立董事一致同意，可免除前述通知期限要求。 第五条 独立董事专门会议应当由过半数独立董事共同推举一名独立董事召 集和主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召集并 推举一名代表主持。 第六条 独立 ...

证券代码：300451 证券简称：创业慧康 公告编号： 2024-010 一、利润分配方案基本情况 经天健会计师事务所（特殊普通合伙）审计，公司 2023 年度实现净利润 45,687,075.62 元，其中母公司实现净利润-47,211,941.29 元，根据《公司章程》 规定，按 10%提取法定盈余公积金 0 元后，当年实现未分配利润为-47,211,941.29 元，加上年初可供未分配利润 1,008,194,729.92 元，扣除 2023 年 5 月已实施的 2022 年度利润分配 15,468,480.24 元，加上其他综合收益结转留存收益 53,051.12 元，公司截至 2023 年 12 月 31 日可供分配利润为人民币 945,567,359.51 元，资 本公积金人民币 1,660,979,352.00 元。 经统筹考虑公司资金使用情况，2023 年利润分配预案为：以公司总股本剔 除回购证券专用账户的股份为基数，向全体股东每 10 股派发现金股利 0.1 元（含 税），不送红股，不以公积金转增股本，剩余未分配利润结转以后年度分配。 自 2023 年年度利润分配方案披露之日起至实施权益分派 ...